Human Endothelin Testing: Principles, Methods, and Clinical Applications

Human endothelin testing is a specialized laboratory assay used to quantify endothelin peptides, particularly endothelin-1 (ET-1), which is one of the most potent vasoconstrictors produced by vascular endothelial cells. Accurate measurement of endothelin levels provides critical insights into cardiovascular, renal, pulmonary, and obstetric pathologies, making it an essential tool in both clinical diagnostics and biomedical research.

Technical Overview

Human endothelin testing refers to the laboratory quantification of endothelin family peptides in biological specimens. The endothelin system comprises three 21-amino acid isopeptides—endothelin-1 (ET-1), endothelin-2 (ET-2), and endothelin-3 (ET-3)—along with two G-protein-coupled receptors, ETA and ETB. Among these, ET-1 is the most clinically significant isoform and is predominantly secreted by vascular endothelial cells, although it is also produced by smooth muscle cells, macrophages, renal epithelial cells, and certain malignant tissues.

ET-1 is generated through proteolytic processing: preproendothelin is cleaved to big endothelin-1 (big ET-1), a 38-amino acid precursor, which is subsequently converted to mature ET-1 by endothelin-converting enzyme (ECE). Because mature ET-1 has a plasma half-life of less than two minutes, many laboratories measure big ET-1 as a more stable surrogate marker that correlates well with ET-1 activity.

Under physiological conditions, circulating ET-1 concentrations are very low, typically below 5 pg/mL in plasma. Elevated levels are associated with endothelial dysfunction and have been documented in hypertension, pulmonary arterial hypertension, heart failure, atherosclerosis, chronic kidney disease, diabetes mellitus with vascular complications, preeclampsia, and various malignancies. Consequently, endothelin testing serves both as a biomarker of endothelial injury and as a research tool for evaluating therapeutic agents targeting the endothelin axis.

Testing Samples

Plasma

Plasma is the preferred specimen for systemic endothelin measurement. Venous blood should be collected into pre-chilled tubes containing EDTA as an anticoagulant, ideally supplemented with aprotinin or another protease inhibitor to minimize ex vivo degradation. Because platelets release ET-1 during clotting, plasma is strongly recommended over serum to avoid falsely elevated results. Samples must be centrifuged promptly at 4°C, and the resulting plasma should be aliquoted and stored at -70°C or colder to preserve peptide integrity.

Serum

Serum samples may be used when plasma collection is impractical, but interpretation requires caution. During the clotting process, platelet activation and release of intracellular ET-1 can artificially raise measured concentrations by a substantial margin. If serum is used, standardized clotting time and rapid processing are essential, and results should be compared against serum-specific reference ranges.

Urine

Urinary ET-1 reflects renal synthesis of the peptide rather than filtered plasma levels, making it useful for evaluating intrarenal endothelin activity. Random spot urine samples corrected for creatinine or timed 24-hour collections may be employed. Urinary measurement is particularly relevant in studies of diabetic nephropathy, contrast-induced nephropathy, and salt-sensitive hypertension.

Cell Culture Supernatant

In research settings, conditioned media from cultured endothelial cells, vascular smooth muscle cells, or tumor cells can be assayed to quantify endothelin secretion. Serum-free or low-serum culture conditions are recommended for 24 to 48 hours prior to collection to reduce background interference from growth factors present in fetal bovine serum.

Tissue Homogenate

Tissue specimens, including vascular biopsies, kidney tissue, and tumor samples, may be homogenized under cold conditions in buffered solutions containing protease inhibitors. Tissue endothelin content provides localized information about peptide production and is often normalized to total protein concentration.

Testing Items

Commonly ordered endothelin testing items include the following:

• Endothelin-1 (ET-1): the primary clinical marker of endothelial activation and vasoconstrictor activity.
• Big Endothelin-1 (Big ET-1): the stable precursor fragment, widely used as a surrogate for mature ET-1 due to its longer half-life.
• Endothelin-2 (ET-2): measured mainly in research contexts, with noted relevance in ovarian and renal physiology.
• Endothelin-3 (ET-3): primarily investigated in neural crest development studies and certain neuroendocrine research applications.
• Endothelin Converting Enzyme (ECE) activity: an enzymatic assay used in pharmacological and mechanistic studies.
• Endothelin Receptor Expression (ETA/ETB): assessed by molecular methods in research on receptor-mediated vascular tone regulation.

Most clinical applications focus on ET-1 or big ET-1 quantification, while the other analytes are typically restricted to specialized research protocols.

Testing Methods

Enzyme-Linked Immunosorbent Assay (ELISA)

ELISA is the most widely used method for human endothelin detection due to its safety, throughput, and absence of radioactive materials. Competitive or sandwich ELISA formats are available, with detection limits typically reaching the low pg/mL range. Samples usually require extraction or concentration steps because circulating ET-1 levels are extremely low. A common workflow involves acidified extraction using C18 solid-phase columns, followed by competitive binding with an ET-1-specific antibody and colorimetric or fluorometric detection. Well-validated commercial kits demonstrate intra-assay coefficients of variation below 10 percent and inter-assay variation below 15 percent.

Radioimmunoassay (RIA)

RIA was the classical method for endothelin quantification and remains in use in some reference laboratories. It employs radiolabeled ET-1 competing with sample ET-1 for binding to a high-affinity antibody, with radioactivity measured in a gamma counter. RIA offers excellent sensitivity but requires radioisotope handling infrastructure, licensing, and strict waste management, which has driven the shift toward non-isotopic alternatives.

Chemiluminescence Immunoassay (CLIA)

Chemiluminescent platforms enhance analytical sensitivity beyond conventional colorimetric ELISA, with detection limits approaching 0.1 pg/mL. Automated CLIA systems improve reproducibility and turnaround time, making this approach suitable for higher-volume clinical laboratories and longitudinal patient monitoring.

Pre-Analytical Considerations and Quality Control

Robust pre-analytical control is decisive for reliable endothelin results. Key requirements include:

• Collection into chilled EDTA tubes with protease inhibitors to prevent degradation and ex vivo release.
• Centrifugation within 30 to 60 minutes of venipuncture at refrigerated temperatures.
• Avoidance of hemolyzed samples, since erythrocyte proteases and released contents interfere with immunoassay binding.
• Storage at -70°C with avoidance of repeated freeze-thaw cycles, which degrade the peptide.
• Use of extraction procedures when assay sensitivity is insufficient for direct plasma measurement.
• Inclusion of calibration curves, internal quality controls, and participation in external quality assessment programs where available.

Cross-reactivity between ET-1, ET-2, and ET-3 is an important analytical variable. Assays marketed as ET-1-specific should document minimal cross-reactivity with related isoforms and big ET-1, and laboratories should verify lot-specific performance before clinical reporting.

Applications

Cardiovascular Disease

Elevated plasma ET-1 correlates with hypertension severity, atherosclerotic burden, acute coronary syndromes, and heart failure prognosis. In heart failure, persistently high ET-1 levels are associated with pulmonary vasoconstriction, disease progression, and adverse outcomes, supporting risk stratification and therapeutic monitoring.

Pulmonary Arterial Hypertension

ET-1 is a central mediator of pulmonary vascular remodeling. Measurement of plasma ET-1 or big ET-1 assists in evaluating disease severity and monitoring response to endothelin receptor antagonists such as bosentan, ambrisentan, and macitentan, which are cornerstone therapies for pulmonary arterial hypertension.

Renal Disease

The endothelin system contributes to renal vasoconstriction, proteinuria, and fibrosis. Urinary and plasma ET-1 measurements are used in research and selected clinical settings to assess diabetic nephropathy, contrast-induced nephropathy, chronic kidney disease progression, and the efficacy of nephroprotective interventions.

Obstetric Complications

In preeclampsia, placental ET-1 production is markedly increased, and maternal plasma levels correlate with disease severity, making endothelin testing valuable in studying and, in some centers, monitoring hypertensive disorders of pregnancy.

Cerebrovascular Vasospasm

Following subarachnoid hemorrhage, elevated ET-1 levels are implicated in delayed cerebral vasospasm. Serial measurements have been applied in research protocols to identify patients at risk and evaluate vasospasm prophylaxis.

Oncology Research

ET-1 is overexpressed in prostate, ovarian, breast, colorectal, and other malignancies, where it promotes proliferation, angiogenesis, and osteoblastic metastasis. Endothelin quantification in tumor tissue and plasma supports translational studies, including trials of ETA receptor antagonists in advanced cancer.

Drug Development and Pharmacology

Pharmaceutical studies rely on endothelin assays to characterize endothelin receptor antagonists, ECE inhibitors, and compounds affecting nitric oxide–endothelin balance. The assay supports pharmacodynamic biomarker development across cardiovascular and renal drug programs.

FAQ

What is the normal reference range for plasma endothelin-1?

Reference intervals vary by assay and specimen preparation, but fasting plasma ET-1 concentrations in healthy adults are generally below 5 pg/mL, with many laboratories reporting typical values between 1 and 3 pg/mL. Each facility must establish or verify its own reference range using its specific analytical platform and pre-analytical protocol.

Why is plasma preferred over serum for endothelin testing?

Platelets store and release ET-1 during the clotting process. Serum samples therefore contain significantly higher apparent ET-1 concentrations that do not reflect true circulating levels, whereas prompt plasma separation with EDTA and protease inhibition preserves the in vivo concentration.

Which is better to measure: mature ET-1 or big ET-1?

Mature ET-1 has a very short plasma half-life, making it analytically challenging. Big ET-1 is more stable, has a longer half-life of approximately 15 to 20 minutes, and correlates closely with ET-1 production. Many laboratories prefer big ET-1 for this reason, particularly in longitudinal monitoring.

Do medications affect endothelin test results?

Yes. Endothelin receptor antagonists, ACE inhibitors, angiotensin receptor blockers, diuretics, and vasoactive drugs can all influence endothelin levels. Clinicians should document current pharmacotherapy when interpreting results, and research protocols frequently require standardized washout periods.

Can endothelin testing be used alone for diagnosis?

No. Endothelin measurement is a supportive biomarker rather than a stand-alone diagnostic test. Results must be interpreted alongside clinical presentation, imaging, hemodynamic data, and other laboratory findings. Its greatest value lies in risk stratification, pathophysiological research, and therapeutic monitoring.

How should samples be shipped to the testing laboratory?

Processed plasma, serum, urine, or tissue specimens should be shipped frozen on dry ice with temperature monitoring. Repeated freeze-thaw cycles must be avoided, and all specimens should be labeled with collection time, anticoagulant type, and relevant clinical information to ensure valid interpretation.